Sumitomo Pharma (TYO:4506) raised its forecast for fiscal 2025, including an attributable profit of 23.6 billion yen or 59.49 yen per share, driven by stronger-than-expected sales of prostate cancer drug and other products in North America, according to its filing on Tuesday.
This compares with the 16 billion yen or 40.27 yen per share previously forecasted.
Revenue is now expected at 398.8 billion yen from 381 billion yen initially.
A key boost came from the 11.9 billion yen gain recorded after transferring its regenerative medicine business to Racthera and Sumitomo Chemical in February.
This strategic move, alongside robust pharmaceutical performance, marks a turnaround from fiscal 2024's 314.9 billion yen net loss.
Shares of the company surged nearly 15% in morning trade Wednesday.
Price (JPY): $787.00, Change: $+100, Percent Change: +14.56%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。